RXi Pharmaceuticals Corp (RXII) Issued to Announce Quarterly Revenue on Thursday

RXi Pharmaceuticals Corp (RXII) Issued to Announce Quarterly Revenue on Thursday

RXi Pharmaceuticals Corp (NASDAQ:RXII) is set to issue its quarterly earnings data after the market closes on Thursday, March 30th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

RXi Pharmaceuticals Corp (NASDAQ:RXII) opened at 0.865 on Wednesday. The firm’s market cap is $5.71 million. The stock’s 50 day moving average price is $0.74 and its 200 day moving average price is $1.14. RXi Pharmaceuticals Corp has a 1-year low of $0.60 and a 1-year high of $3.27.

RXi Pharmaceuticals Corp Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Related posts

Leave a Comment